ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 720,55
-0,27%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Inhibikase Therapeutics Inc (IKT)

  7. Inhibikase Therapeutics Inc (IKT) Actualités

IKT Inhibikase Therapeutics Inc

1,39
0,05 (3,73%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Inhibikase Therapeutics Inc IKT NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,05 3,73% 1,39 06:00:10
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,38 1,3304 1,51 1,39 1,34
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
18/4/202422:30GLOBEInhibikase Therapeutics Issues Letter to Shareholders and..
03/4/202414:05GLOBEInhibikase Therapeutics Announces Pre-IND Meeting with the..
27/3/202421:15GLOBEInhibikase Therapeutics Reports Fourth Quarter and Full Year..
07/3/202414:30GLOBEInhibikase Therapeutics to Provide Trial Update for..
28/2/202422:05GLOBEInhibikase Therapeutics Announces Full Outcomes of its..
07/2/202413:59EDGAR2Form 8-K - Current report
07/2/202413:55GLOBEInhibikase Therapeutics Announces Preliminary Outcomes of..
01/2/202422:49EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/2/202422:09EDGAR2Form 8-K - Current report
29/1/202415:05GLOBEInhibikase Therapeutics Announces Publication Highlighting..
16/1/202422:31EDGAR2Form 8-K - Current report
16/1/202422:05GLOBEInhibikase Therapeutics Announces Planned Retirement of..
19/12/202314:30GLOBEInhibikase Therapeutics Issues Letter to Shareholders and..
04/12/202314:35GLOBEInhibikase Therapeutics Granted Pre-NDA Meeting with the FDA..
14/11/202322:30GLOBEInhibikase Therapeutics Reports Third Quarter Financial..
07/11/202315:28GLOBECorrecting & Replacing -- Inhibikase Therapeutics to Report..
07/11/202314:00GLOBEInhibikase Therapeutics to Report Second Quarter Financial..
16/10/202323:24EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
16/10/202313:00GLOBEInhibikase Therapeutics Highlights Unblinded Functional..
04/10/202314:30GLOBEInhibikase Therapeutics Receives FDA Orphan Drug Designation..
20/9/202317:23EDGAR2Form 8-K - Current report
24/8/202314:30PRNUSInhibikase Therapeutics Announces Development of Novel..
22/8/202314:05PRNUSInhibikase Therapeutics to Present at the International..
21/8/202314:30PRNUSInhibikase Therapeutics Initiates Development of Second..
17/8/202314:30PRNUSInhibikase Therapeutics Announces Completion of the 501..
14/8/202322:20PRNUSInhibikase Therapeutics Reports Second Quarter Financial..
14/8/202322:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202314:05PRNUSInhibikase Therapeutics to Report Second Quarter Financial..
17/7/202323:29EDGAR2Form 8-K - Current report
17/7/202322:05PRNUSInhibikase Therapeutics Regains Compliance with Nasdaq..
06/7/202303:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/7/202303:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/6/202318:15EDGAR2Form 8-K - Current report
29/6/202315:29PRNUSInhibikase Therapeutics Announces a 1-for-6 Reverse Stock..
22/6/202314:05PRNUSInhibikase Therapeutics Announces Selection of the..
21/6/202314:05PRNUSInhibikase Therapeutics Initiates Medical and Patient..
30/5/202314:05PRNUSInhibikase Therapeutics to Present at the LD Micro..
16/5/202313:45PRNUSInhibikase Therapeutics Announces Dosing of First Patient in..
15/5/202314:30PRNUSInhibikase Therapeutics Reports First Quarter Financial..
08/5/202314:05PRNUSInhibikase Therapeutics to Report First Quarter Financial..

Dernières Valeurs Consultées

NASDAQ
IKT
Inhibikase Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés